Suvretta Capital Management LLC Has $10.55 Million Stake in Molecular Partners AG (NASDAQ:MOLN)

Suvretta Capital Management LLC boosted its position in shares of Molecular Partners AG (NASDAQ:MOLN) by 455.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,221,494 shares of the company’s stock after buying an additional 1,821,494 shares during the period. Suvretta Capital Management LLC owned approximately 0.06% of Molecular Partners worth $10,548,000 at the end of the most recent quarter.

Separately, BVF Inc. IL lifted its holdings in shares of Molecular Partners by 205.5% in the fourth quarter. BVF Inc. IL now owns 1,353,968 shares of the company’s stock worth $6,458,000 after acquiring an additional 910,747 shares during the last quarter. 26.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Lifesci Capital started coverage on shares of Molecular Partners in a report on Tuesday, March 11th. They issued an “outperform” rating and a $12.00 target price for the company.

Molecular Partners Trading Down 0.3%

MOLN stock opened at $3.84 on Friday. The stock has a market capitalization of $155.04 million, a P/E ratio of -1.79 and a beta of 1.15. Molecular Partners AG has a 12 month low of $3.36 and a 12 month high of $12.70. The firm has a 50-day moving average price of $3.96 and a 200-day moving average price of $4.84.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.11). Molecular Partners had a negative net margin of 1,043.01% and a negative return on equity of 39.31%. As a group, equities analysts predict that Molecular Partners AG will post -1.93 EPS for the current fiscal year.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.